{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T17:09:12Z","timestamp":1765040952718,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.exphem.2019.09.025","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T19:22:25Z","timestamp":1569525745000},"page":"26-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat"],"prefix":"10.1016","volume":"79","author":[{"given":"Suzanne","family":"McPherson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme","family":"Greenfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7753-6768","authenticated-orcid":false,"given":"Christen","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Grinfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans C.","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti","family":"Nangalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken I.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0773-0204","authenticated-orcid":false,"given":"Mary F.","family":"McMullin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2019.09.025_bib0001","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2019.09.025_bib0002","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.exphem.2019.09.025_bib0003","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.exphem.2019.09.025_bib0004","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2014.113845","article-title":"Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms","volume":"102","author":"Grinfeld","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2019.09.025_bib0005","first-page":"e38","article-title":"Implications of mutation profiling in myeloid malignancies: Part 1","volume":"32","author":"Tremblay","year":"2018","journal-title":"Myelodysplastic syndromes and acute myeloid leukemia. Oncology (Williston Park)"},{"key":"10.1016\/j.exphem.2019.09.025_bib0006","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2019.09.025_bib0007","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccr.2010.12.020","article-title":"JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation","volume":"19","author":"Liu","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2019.09.025_bib0008","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nature08448","article-title":"JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin","volume":"461","author":"Dawson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2019.09.025_bib0009","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1182\/blood-2017-10-810622","article-title":"Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms","volume":"131","author":"Peeken","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2019.09.025_bib0010","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3324\/haematol.2013.084160","article-title":"Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms","volume":"98","author":"P\u00e9rez","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2019.09.025_bib0011","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2019.09.025_bib0012","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00277-017-2994-x","article-title":"Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study","volume":"96","author":"Vannucchi","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.exphem.2019.09.025_bib0013","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1182\/blood-2017-05-785790","article-title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide","volume":"130","author":"Harrison","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2019.09.025_bib0014","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/0008-5472.CAN-03-2043","article-title":"Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824","volume":"64","author":"Atadja","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2019.09.025_bib0015","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.leu.2403910","article-title":"Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors","volume":"19","author":"Bradbury","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2019.09.025_bib0016","doi-asserted-by":"crossref","first-page":"11700","DOI":"10.1073\/pnas.182372299","article-title":"The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin","volume":"99","author":"Butler","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2019.09.025_bib0017","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bjh.12416","article-title":"A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia","volume":"162","author":"Andersen","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2019.09.025_bib0018","doi-asserted-by":"crossref","first-page":"R115","DOI":"10.1186\/gb-2013-14-10-r115","article-title":"DNA methylation age of human tissues and cell types","volume":"14","author":"Horvath","year":"2013","journal-title":"Genome Biol"},{"key":"10.1016\/j.exphem.2019.09.025_bib0019","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/gb-2014-15-2-r24","article-title":"Aging of blood can be tracked by DNA methylation changes at just three CpG sites","volume":"15","author":"Weidner","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.exphem.2019.09.025_bib0020","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12967-018-1729-7","article-title":"The ruxolitinib effect: Understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms","volume":"16","author":"Greenfield","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.exphem.2019.09.025_bib0021","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1101\/gr.103606.109","article-title":"Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer","volume":"20","author":"Teschendorff","year":"2010","journal-title":"Genome Res"},{"key":"10.1016\/j.exphem.2019.09.025_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/leu.2013.242","article-title":"Origins of aberrant DNA methylation in acute myeloid leukemia","volume":"28","author":"Schoofs","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2019.09.025_bib0023","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2019.09.025_bib0024","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2019.09.025_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001576","article-title":"Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion","volume":"11","author":"Kent","year":"2013","journal-title":"PLoS Biol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X19310276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X19310276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:34:14Z","timestamp":1759566854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X19310276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":25,"alternative-id":["S0301472X19310276"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2019.09.025","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2019.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}